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Abstract
Background: Hypercholesterolemia, particularly high LDL-c and non-HDL-c levels, is a traditional risk for cardiovascular
disease. Ingestion of diets containing phytosterols and inulin can reduce plasma LDL-c and triglyceride levels,
respectively. Phytosterols and inulin-enriched soymilk may be an alternative for a supplemental diet to improve both
LDL-c and non-HDL-c to reduce the risk of cardiovascular disease.
Methods: Two hundred and forty subjects who were 18 years old or older and had a baseline LDL-c of 130 mg/dl or
higher were enrolled into the double-blinded randomized controlled trial study. Subjects were randomly assigned into
the study group that received 2 g/day of phytosterols and 10 g/day of inulin-enriched soymilk or into the control
group that received standard soymilk. The lipid profile was measured every 2 weeks for 8 weeks. Primary outcomes
were 1) to determine the LDL-c reduction after consumption of phytosterols and inulin-enriched soymilk for 8 weeks
and 2) to compare the difference of the LDL-c levels between the study and control groups. The secondary outcomes
were to compare the difference of TC, TG and HDL-c between the study and control groups.
Results: At the end of the study, the median LDL-c levels decreased significantly from 165 (132, 254) mg/dl to 150
(105, 263) mg/dl in the study group (p < 0.001) and from 165 (130, 243) mg/dl to 159 (89, 277) mg/dl in the control
group (p = 0.014). The LDL-c reduction was significantly better in the study group (−10.03 %, (−37.07, 36.00) vs −1.31 %
(−53.40, 89.73), p < 0.001). TC also reduced significantly by 6.60 % in the study group while it reduced only by 1.76 % in
the control group (p < 0.001). There were no statistical differences in TG and HDL-c levels between both study groups.
The adverse events in the study group and the control groups were not different (RR 1.33 [0.871-2.030, 95 % CI]).
Conclusion: Daily consumption of soymilk containing 2 g of phytosterols and 10 g of inulin reduced TC and LDL-c
better than standard soymilk. It had no effect on TG and HDL-c levels compared to standard soymilk. Both soymilk
products were comparably safe.
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Background
Hypercholesterolemia, particularly low-density lipopro-
tein cholesterol (LDL-c), is an important risk factor for
cardiovascular disease. In addition to lipid-lowering
agents, recent guidelines have suggested to intake a diet
which includes 2 g/day of phytosterols including plant
sterol and plant stanol to decrease LDL-c [1–4]. Phytos-
terols are sterols from plants which are unable to be syn-
thesized by the human body, thus it is necessary to add
them (e.g., nuts, legumes and seeds) to the diet [5]. The
structure of phytosterols is similar to cholesterol [6]
(Fig. 1) and they compete with the cholesterol to incorp-
orate into mixed micelles formation inside the intestinal
lumen. Finally micelles containing phytosterols are
absorbed into the enterocytes through the Niemann-
Pick C1-like 1 (NPC1L1) dependent pathway but phy-
tosterols will efflux back into the intestinal lumen
through heterodimeric sterol transporter ABCG5/
ABCG8 [ATP-binding cassette (ABC) transporters G5
and G8] [7]. With this process, the ingestion of 2–2.5 g/
day of phytosterols in the diet can reduce plasma LDL-c
levels by 8-15 % in patients with or without a concomi-
tant statin [8, 9]. From a meta-analysis, the LDL-c re-
duction effect depended on the amount of phytosterols
ingested and the effect was sustained after the intake of
2 g or more per day of phytosterols [10]. Phytosterols
have a neutral effect on the triglyceride (TG) or high-
density lipoprotein cholesterol (HDL-c) levels in plasma
[11]. There is a lack of data on phytosterols content in
the Thai diet which should be lower than the western
diet that usually contains 150–450 mg of phytosterols
per day; however, the total amount of phytosterols in the
western diet is inadequate according to recent guideline
recommendations. Phytosterols-enriched soymilk is an
alternative method to increase the total phytosterols in-
take to meet the adequate amount recommended in the
guidelines.
A relationship between the TG level and the incidence
of cardiovascular disease (CVD) is still controversial but
there was evidence of stronger links between hypertri-
glyceridemia and CVD risk in people with lower levels
of HDL-c and LDL-c [12, 13] and with type 2 diabetes
mellitus (T2DM) [14]. The National Lipid Association
(NLA) Expert Panel recommendations also indicated
that the normal level of serum TG was less than
150 mg/dl [15].
Inulin-type fructans, which are nondigestible carbohy-
drates, are capable of decreasing TGs by many mecha-
nisms including 1) decreased hepatic lipogenesis, 2)
increased muscle lipoprotein lipase activity and 3) in-
creased short chain fatty acids by bacterial fermentation
of carbohydrates which is also capable of inhibiting TG
synthesis [16]. In a human study, adding 10 g of high-
performance inulin into a moderately high-carbohydrate,
Fig. 1 Structure of phytosterols (sitosterol and sitostanol)
Kietsiriroje et al. Lipids in Health and Disease  (2015) 14:146 Page 2 of 13
low-fat diet in 8 healthy subjects decreased the TG level
by inhibiting hepatic lipogenesis [17]. A meta-analysis
that included 15 studies concluded that the intake of
inulin-type fructans (average amount of inulin was
14.2 g/day [range 4–32]) was associated with a significant
decrease in the TG level by 15.05 mg/dl [18]. However,
the triglyceride-lowering effect of inulin is inconsistent
among trials and is still inconclusive [16, 18, 19]. Thus,
the phytosterols and inulin-enriched soymilk may be an
alternative to supplement the diet to improve both LDL-c
and non-HDL-c to reduce the risk of cardiovascular
disease.
Much data confirmed the effects of phytosterols or
inulin-enriched products on the lipid profile in many
ethnicities but this effect among the Thai population
lacks data. This research aims to confirm the effect of
phytosterols and inulin on the lipid profile among the
Thai population after ingesting phytosterols and inulin-
enriched soymilk for 8 weeks.
Methods
Study design
This was a double-blinded, randomized-controlled trial
that enrolled 240 adult volunteers from the outpatient
department and the Endocrinology and Metabolism Unit
of Songklanagarind Hospital at Prince of Songkla Uni-
versity from 28 May 2013 to 5 June 2014. The inclusion
criteria were 1) subjects who were 18 years old or older
and 2) subjects whose LDL-c levels were 130 mg/dl or
higher. None of patients were taking statins. The exclusion
criteria were 1) subjects who had established cardiovascu-
lar disease, 2) subjects who had any type of diabetes melli-
tus, 3) subjects who had gastrointestinal dysmotility, 4)
subjects who had abnormal gastrointestinal digestion or
absorption, 5) subjects who had an allergy to soymilk and
6) subjects who had secondary hyperlipidemia such as
hypothyroidism, nephrotic syndrome or hepatic disease.
Withdrawal or termination criteria were 1) subject’s
intention to withdraw, 2) subjects loss to follow-up, 3) ele-
vated transaminase enzymes >3 fold of the upper normal
limits, 4) reduced glomerular filtration rate ≥1 stage by
the Kidney Disease Outcomes Quality Initiative criteria, 5)
subjects unable to tolerate adverse events from soymilk
products and 6) compliance of subjects less than 80 % per
visit. This study was approved by the Songklanagarind
Hospital ethics committee. Written informed consents
were obtained before screening and randomization.
The study subjects were randomly assigned by a third-
party into the study group which received phytosterols
and inulin-enriched soymilk or into the control group
which received standard soymilk. The simple random
sampling was used to generate a number sequence by
the sponsor and the number sequence was given for
randomization with an allocation ratio of 1:1. The
intervention assignments were concealed to both sub-
jects and clinical staff before randomization. All subjects
were given instructions to drink soymilk products twice
daily, once in the morning and once in the evening. Sub-
jects who consumed soymilk products less than 80 %
were determined as non-compliance.
Soymilk products
The phytosterols and inulin-enriched soymilk (UHT
SOY MILK WITH PHYTOSTEROL; DNA®, Thai FDA
food registration number 60-1-05841-2-0089) and stand-
ard soymilk in this study were supplied by Dairy Plus
Company Limited. A serving unit of both soymilk prod-
ucts contained 180 ml of soymilk, 4.5 g of fat, 5 g of pro-
tein and 12 g of carbohydrate. In addition, a serving unit
of the phytosterols and inulin-enriched soymilk contained
1 g of phytosterols and 5 g of inulin. The components of
the soymilk products are shown in Tables 1 and 2.
Data collection at baseline before randomization
Subjects who met the inclusion criteria at the screening
visit proceeded to history taking and blood pressure and
anthropometry measurements that included body mass
index (BMI), waist circumference (WC) and hip circum-
ference (HC) by well-trained personnel. Blood samples
for laboratory testing were drawn after fasting for 12 h
at screening. All subjects were requested by a nurse to
record their eating and exercise behaviors through a 7-
day diet and physical activity questionnaire for 1 week
before randomization (week 0).
Follow-up data after randomization
At randomization, all subjects were given guidance to
change their eating and exercise behaviors and record
them in the 7-day diet and physical activity questionnaire.
All subjects had to follow-up at the clinic every 2 weeks
for 8 weeks. At each follow-up, all subjects were inter-
viewed for adverse events and underwent a related phys-
ical examination. The blood pressure and anthropometry
measurements were also taken every visit. Blood samples
for biochemistry testing were drawn after fasting for 12 h
at weeks 2, 4, 6 and 8. The 75 g oral glucose tolerance
tests were conducted at the randomization time (week 0).
Anthropometry measurements
Well-trained personnel measured the WC and HC. The
waist circumference was measured at midline between
the lower ribs and the iliac crest during expiration. The
hip circumference was measured at the widest part of
the hip. The BMI was computed from body weight and
height and the waist-hip ratio was computed from the
WC and HC measurements.
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Biochemistries
Venous blood samples were drawn between 08:00
and10:00 after a 12-h fast. Serum aliquots were stored at
room temperature and transported to the laboratory for
testing on the same day. Fasting plasma glucose (FPG),
total cholesterol (TC), TG, HDL-c and LDL-c levels were
measured by enzymatic in vitro assay for direct determin-
ation using a MODULAR P800 analyzer. The interassay
coefficients of variation of the fasting plasma glucose, total
cholesterol, triglyceride, HDL-c and LDL-c were 1.48-
1.52 %, 1.57-1.59 %, 1.62-1.71 %, 2.22-2.35 % and
1.96-2.19 %, respectively.
Adverse events
The subjects were asked every 2 weeks about adverse
events including abdominal pain, bloating, nausea,
vomiting and increased frequency of defecation or diar-
rhea when they visited the clinic. Transaminase enzymes
and renal function tests were performed every 2 weeks to
monitor for any serious adverse events. A serious adverse
event was defined by an adverse event which led to with-
drawal or termination of the patient from the study.
Outcomes
Primary outcomes were 1) to compare the LDL-c levels
of subjects before and after consumption of the phytos-
terols and inulin-enriched soymilk for 8 weeks and 2) to
compare the LDL-c levels in subjects who consumed the
phytosterols and inulin-enriched soymilk to the subjects
who consumed standard soymilk. Secondary outcomes
were to compare the TC, TG and HDL-c levels in sub-
jects who consumed phytosterols and inulin-enriched
soymilk to the subjects who consumed standard soymilk.
The potential confounders on the change in the lipid
profile included age, sex, BMI and hypertension.
Sample size calculation
The sample size of the study was calculated using the
formula illustrated below.





¼ 2 1:96þ 0:84ð Þ26:3½ 2=95:0625
¼ 114 pairs
2–tailed studyα ¼ 0:05; Zα ¼ 1:96; β ¼ 0:20; Zβ
¼ 0:84
To calculate all variables in the formula, we used data
referring to the Weidner, C. et al. study [20]. The mean
LDL-c level in subjects who consumed phytosterols and
inulin-enriched soymilk for 8 weeks decreased from 164
± 25 mg/dl to 152.9 ± 24 mg/dl while the mean LDL-c
level in subjects who consumed standard soymilk de-
creased from 160 ± 25 mg/dl to 159.5 ± 28.5 mg/dl. The
mean difference of the LDL-c between the groups was
9.75 mg/dl.
















The dropout rate was set to be at least 5 %, thus
the total number of subjects in this study was calcu-
lated to be approximately 240 subjects (120 subjects
in each arm)






- Soy milk 93.3 93.3
- Inulin 3 0
- Sugar 2.5 2.5
- Calcium 0.7 0.7
- Oat flour 0.03 0.03
- Vitamin complex 0.03 0.03
- Green Tea extract 0.015 0.015
- Wheat Grass extract 0.0005 0.0005
- Phytosterols 0.55 (100 %) 0
o Total sterol esters 91 %
o Free sterols 6 %
Table 2 Sterol composition of UHT SOY MILK WITH
PHYTOSTEROL; DNA®
Sterol compositiona (as free sterols) By GC, rel. area (%)
Cholesterol 0.0 – 2.0
Brassicasterol 2.0 – 6.0
Campesterol 20.0 – 29.0
Campestanol 0.0 – 6.0
Stigmasterol 12.0 – 23.0
Beta-sitosterol 42.0 – 55.0
Sitostanol 0.0 – 2.5
D5-Avenasterol 0.0 – 4.0
D7-stigmastenol 0.0 – 2.0
D7-Avenasterol 0.0 – 2.0
Other sterols 0.0 – 5.0
a according Food Chemical Codex Monograph
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Statistical analysis
Descriptive data were showed in mean, median, standard
deviation (SD) and range (min,max). The likelihood ratio
test or Fisher’s exact test was used to identify differences
between the baseline characteristics which were categor-
ical data and the Mann–Whitney U test was used in case
of continuous data. The statistical analysis to determine
the difference of LDL-c and other lipids between the
study groups used the Mann–Whitney U test. The statis-
tical analysis to determine the difference of LDL-c
between pre- and post-intervention in each study group
used the Wilcoxon signed-rank test. Multiple linear
regression was used to adjust potential confounders
including age, sex, BMI and hypertension, using the base-
line LDL-c value as a covariate. A change-in-estimation
criterion with a cut-off of 10 % was used to identify the
confounders [21]. Pearson correlation was used to deter-
mine the correlation between baseline LDL-c and percent
LDL-c change. Pearson Chi-square was used to determine
the relative risk of adverse events between groups. A
p-value <0.05 indicated statistical significance. R-3.1.2
for Windows was used for the data analyses.
Results
Two hundred and seventy-three volunteers were
screened. The number of subjects who met the inclusion
criteria and enrolled into the study was 240. The en-
rolled subjects were 1:1 randomized into the study group
or the control group which put 120 subjects in each
group. Thirteen subjects (5.42 %) withdrew from the
study; 4 subjects had serious adverse events, 5 subjects
were loss to follow-up, 1 subject was noncompliant and
3 subjects requested withdrawal from the study because
of pregnancy, anterior cruciate ligament surgery and the
inconvenience of drinking a soymilk product. Two hun-
dred and twenty-seven subjects (94.58 %) were included
into the primary outcome analysis (Fig. 2).
Demographic and baseline characteristics of the sub-
jects are shown in Table 3. Subjects were predominantly
female (85 %); 57.5 % of the subjects were government
employees and 19.16 % of the subjects were university
employees. Cardiovascular risk factors of the subjects in
the study were 91.67 % of the subjects never smoked,
3.75 % of the subjects reported they had hypertension,
9.09 % of the subjects reported dyslipidemia and 2.5 %
of the subjects reported a family history of cardiovascu-
lar disease. The median age of the subjects was 47.5
(18,71) years old, mean BMI was 24.20 ± 3.48 kg/m2,
median WC was 82.5 (60,122) cm, median systolic blood
pressure was 117 (87,176) mmHg and median diastolic
blood pressure was 72 (36,117) mmHg, median FPG was
90 (71,114) mg/dl and the median LDL-c level was 165
(130,254) mg/dl. There were no differences in the demo-
graphic and baseline characteristic data between the
study group and the control group except the report of
dyslipidemia in the study group was higher than the
control group (12.5 % vs 4.17 %, p = 0.033).
At the end of the study, the median LDL-c levels de-
creased significantly from 165 (132,254) mg/dl to 150
(105,263) mg/dl in the study group (p < 0.001) and from
165 (130,243) mg/dl to 159 (89,277) mg/dl in the control
group (p = 0.014) (Fig. 3). The biweekly lipid profiles in
both groups are shown for comparison in Table 4. The
difference in the LDL-c levels between the groups
started to show at the second week and it persisted until
the end of the study (p < 0.05). The percent LDL-c reduc-
tion in the study group was significantly greater than the
control group (−10.03 % (−37.07, 36.00 %) vs −1.31 %
(−53.40, 89.73 %), p < 0.001) (Table 5) and the LDL-c
reduction efficacy of both soymilk products was also inde-
pendent to potential confounders including age, sex, BMI
and hypertension after they were adjusted (Additional file 1).
Subgroup analysis showed trends of LDL-c reduction were
not different between subgroups defined by 1) with or with-
out hypertension, 2) male or female, 3) normal weight or
over weight (for the Asian population) and 4) younger or
older than 50 years (Fig. 4).
Pearson correlation showed a small but significant cor-
relation between the baseline LDL-c and percent LDL-c
change in the study group (r = −0.23, p-value =0.007).
Linear regression analysis was used to determine the
LDL-c reduction effect of phytosterols and inulin
enriched soymilk and found that for every 1 mg/dl incre-
ment of baseline LDL-c, the LDL-c reduction increased
by 0.11 % (coefficient = −0.11, p-value = 0.014). In the
control group, although there was also a small but
significant correlation found between the baseline LDL-c
and percent LDL-c change (r = −0.27, p-value =0.002), it
should be noted that the LDL-reduction effect of stand-
ard soymilk was seen only if the baseline LDL-c was
over 153 mg/dl while the standard soymilk would
increase LDL-c level among the subjects with lower
baseline LDL-c. This pattern is explained by the ‘regres-
sion to the mean’ phenomenon (Fig. 5).
The phytosterols and inulin-enriched soymilk also sig-
nificantly reduced the TC level compared to standard
soymilk. The percentage of TC reduction in the study
group was 6.60 % while it was only 1.76 % in the control
group (p < 0.001). The TG level did not significantly
change in either group which increased by 0.96 % in the
study group and 0.50 % in the control group (p = 0.96).
The HDL-c level also did not significantly change in ei-
ther group which increased by 1.53 % in the study group
and unchanged in the control group (p = 0.70) (Table 5).
In both study and control groups, the FPG levels were
similar to the baseline levels during the entire study
period and they were not different between the groups
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(Additional file 2). Thirty-one percent of subjects in the
study group had adverse events while 23.3 % of subjects
in the control group had adverse events (relative risk =
1.33 [0.87-2.03, 95 % CI]). There were four serious
adverse events that occurred in the study included one
severe diarrhea in the study group and another in the
control group, one severe bloating in the control group
and one hepatitis (defined by transaminase enzymes that
were 3 fold higher than the upper normal limits) in the
control group. The most common adverse events was
bloating (overall 71.56 %) which seemed to be more
common in the study group (76.92 %) than the control
group (64.72 %) and it seemed to more persistent in the
study group (additional file 3). The adverse events in
each group are shown in Table 6.
Discussion
The present study confirmed LDL-c reduction with 1 g
phytosterols and 5 g inulin-enriched soymilk twice daily
among statin-naïve, mild-to-moderate hypercholesterol-
emia subjects. The absolute LDL-c reduction efficacy of
2 g/day of phytosterols and 10 g/day of inulin was
8.72 % which was comparable to previous studies.
Kriengsinyos W. et al. reported an LDL-c reduction effi-
cacy of 2 g stanol-containing soymilk once a day and
postprandially for 6 weeks that was an absolute 8.9 %
Fig. 2 CONSORT flow diagram
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[22]. The LDL-c reduction efficacy was comparable to
either once daily or twice daily administration as long as
the total dose of phytosterols was 2 g per day. Two
grams daily of phytosterols reduced LDL-c level by 8-
14 %, which depended on the initial baseline LDL-c of
the subjects. At a higher baseline LDL-c, the benefits of
Table 3 Comparison of baseline characteristics, biochemical tests and lipid profiles between groups (n = 240)
Baseline characteristics Number (%) or mean ± SD or median (min,max) p-
valueStudy group (n = 120) Control group (n = 120)
Sexb 0.857
Female 101 (84.2) 103 (85.8)
Male 19 (15.8) 17 (14.2)
age (year), median (min,max)d 48 (24,71) 46 (18,68) 0.75
Careera 0.556
Government employees 73 (60.8) 65 (54.2)
State enterprise employees 1 (0.8) 2 (1.7)
Company employees 5 (4.2) 2 (1.7)
Self-employed 4 (3.3) 2 (1.7)
Servants 12 (10.0) 18 (15.0)
Pensioners 4 (3.3) 5 (4.2)
Students 0 1 (0.8)
University employees 21 (17.5) 25 (20.8)
Smokinga 0.635
Never smoked 109 (92.4) 111 (92.5)
Ex-smoker 4 (3.4) 6 (5.0)
Currently smoked 5 (4.2) 3 (2.5)
Alcohol drinkingb 42 (36.5) 33 (29.7) 0.323
Alcohol drinking in past 12 monthsa 0.310
Every week 2 (6.5) 4 (16.0)
1-3 times/month 5 (16.1) 5 (20.0)
Less than once a month 24 (77.4) 16 (64.0)
Familial history of CVDb 3 (2.5) 3 (2.5) 1.00
Hypertensionb 2 (1.7) 7 (5.8) 0.171
Dyslipidemiab 15 (12.5) 5 (4.2) 0.033*
Body mass index (BMI) (kg./m2)c 23.81 ± 3.26 24.58 ± 3.66 0.085
Waist circumference (WC) (cm) 81 (65,122) 84.25 (60,112) 1.430
Hip Circumference (cm)c 96.70 ± 6.87 97.51 ± 7.10 0.373
Waist hip ratio (WHR)d 0.85 (0.70,0.96) 0.87 (0.73,1.03) 0.322
Systolic blood pressure (mmHg)d 115.50 (92,175) 118 (87,176) 0.409
Diastolic blood pressure (mmHg)d 72 (36,110) 72 (52,117) 0.955
Fasting plasma glucose (mg/dl)d 90 (75,112) 90 (71,114) 0.146
Total cholesterol (mg/dl)c 244.07 (28.92) 239.26 (27.19) 0.238
Triglyceride (mg/dl)d 99.5 (45,295) 97.5 (39,399) 0.904
HDL Cholesterol (mg/dl)c 63.51 (14.96) 60.00 (13.57) 0.207
LDL Cholesterol (mg/dl)d 165 (132,254) 165 (130,243) 0.385
Creatinine (mg/dl)d 0.69 (0.42,1.22) 0.70 (0.51,1.23) 0.258
AST (U/L)d 19 (7,85) 20 (13,66) 0.271
ALT (U/L)d 16 (8,75) 18 (9,81) 0.106
*p < .05, a = likelihood ratio test, b = Fisher’s exact test, c = independent t-test, d = Mann–Whitney U test
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phytosterols were apparently observed [23, 24]. In the
present study, LDL-c reduction efficacy of phytosterols
and inulin enriched soymilk had a small but significant
correlation to baseline LDL-c. Every 1 mg/dl increment
of baseline LDL-c affected the LDL-c reduction by an in-
crease of 0.11 %, while a similar correlation also existed
in the standard soymilk group but it seemed to be a ‘re-
gression to the mean’ phenomenon. The LDL-c level
was significantly lower in the study group from the sec-
ond week and it was constantly lower in the study group
throughout the study period. The action of phytosterols to
inhibit intestinal cholesterol absorption seemed to occur
Fig. 3 Pre- and post-intervention LDL-c levels between the study and control groups at weeks 0 and 8 by Wilcoxon signed-rank test (n = 227)
Table 4 Comparison of total cholesterol, triglyceride, HDL-c and LDL-c between the study and control groups at weeks 0, 2, 4, 6
and 8 (n = 240)
Median (min,max) p-value
Study group (n = 120) Control group (n = 120)
Total cholesterol Week 0 239.5 (191,368) 235 (178,317) 0.238
Week 2 223 (162,336) 235 (167,305) 0.065
Week 4 228 (164,319) 229 (166,316) 0.203
Week 6 225 (118,308) 234 (151,309) 0.011*
Week 8 223.50 (173,335) 232 (147,319) 0.144
Triglyceride Week 0 99.5 (45,295) 97.5 (39,399) 0.904
Week 2 94.0 (41,309) 99.0 (30,364) 0.782
Week 4 92 (34,330) 100 (30,423) 0.438
Week 6 94.5 (41,336) 97 (41,481) 0.512
Week 8 95.5 (38,277) 107 (41,304) 0.494
HDL cholesterol Week 0 61 (34,109) 59 (21,97) 0.207
Week 2 60 (31,99) 58 (32,93) 0.344
Week 4 62 (36,102) 58 (28,92) 0.131
Week 6 63 (33,96) 60 (29,96) 0.082
Week 8 60.5 (35,103) 57 (27,97) 0.174
LDL cholesterol Week 0 165 (132,254) 165 (130,243) 0.385
Week 2 153 (95,256) 165 (91,235) 0.032*
Week 4 150.50 (91,234) 160 (97,244) 0.024*
Week 6 151 (96,223) 163 (93,234) 0.003**
Week 8 150 (105,263) 159 (89,277) 0.009**
Mann–Whitney U test, *p < .05 ** p < .01
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instantly after consuming the phytosterols-enriched soy-
milk. The LDL-c level was also significantly reduced in
subjects who consumed the standard soymilk but its effect
was trivial. This effect probably occurred because 1) the
subjects possibly changed their eating and exercise behav-
iors after enrollment in the study and 2) soy protein in the
standard soymilk had an LDL-c reduction effect [25, 26].
The effect of phytosetrols may be influenced by the
types of food carriers. A previous meta-analysis reported
that high-fat content food carriers might have a greater
effect than low-fat content food carriers [23]. One previ-
ous study demonstrated the LDL-c lowering effects of
phytosterols incorporated into various food carriers, the
absolute LDL-c reductions for yoghurt, hard cheese and
fresh cheese were 7.7 %, 10.9 % and 8.6 %, respectively
[27]. Many reports demonstrated the LDL-c lowering ef-
fects of phytosterols incorporated into low-fat content
food carriers such as low-fat yoghurt [28, 29], milk [29],
yoghurt drinks [30] and orange juice [31], which varied
from 6.4 % to 15.9 %. Hence, the low-fat content food
carriers were good matrixes for incorporation of
phytosterols. Few studies, including the present one, re-
ported the LDL-c lowering effects of 7-13 % of
phytosterols-enriched soymilk on LDL-c which was simi-
lar to other low-fat content food carriers [20, 22, 32].
Thus, soymilk also proved to be a good matrix for incorp-
oration of phytosterols.
LDL-c is a well-known important risk factor for car-
diovascular disease while every 1 mg of LDL-c reduction
relatively decreases the risk of having a coronary event
by 1 % [33]. The phytosterols-enriched soymilk, which
proved its LDL-c reduction effect, may have other effects
to reduce the risk of cardiovascular disease; however,
further investigations are required to determine the car-
diovascular outcome.
High TG and low HDL-c levels are other risk factors
for cardiovascular disease particularly in people with
metabolic syndrome or T2DM. Due to the concern that
the additional carbohydrate and free fatty acid from both
soymilk products might increase the TG levels and lower
the HDL-c levels, the effects of both soymilk products
on TG and HDL-c levels were determined. In the
Table 5 Comparison of percentage changes in the total cholesterol, triglyceride, HDL-c and LDL-c levels between the study and
control groups at week 8 (n = 240)
Median (min,max) p-value*
Study group (n = 120) Control group (n = 120)
Total cholesterol −6.60 (−32.35,35.00) −1.76 (−41.43,34.35) <0.001
Triglyceride 0.96 (−41.14,128.93) 0.50 (−69.42,176.40) 0.96
HDL Cholesterol 1.53 (−53.85,24.59) 0 (−25.42,57.14) 0.70
LDL Cholesterol −10.03 (−37.07,36.00) −1.31 (−53.40,89.73) <0.001
*Mann–Whitney U test
Fig. 4 Subgroup-analysis determined the mean difference of LDL-c reduction between study and control groups based on patients’ hypertension
status, sex, BMI and age (n = 240)
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present study, the phytosterols and inulin-enriched soymilk
and standard soymilk had a neutral effect on both TG and
HDL-c levels which was in agreement with previous stud-
ies [11, 34]. The ESC/EAS guideline also concluded that
2 g daily of phytosterols had little or no effect on TG and
HDL-c levels [3]. However, it should be noted that subjects
recruited into this study were metabolically lean with low
TG and high HDL-c levels and subjects with T2DM were
excluded from the study. Thus, we cannot imply that either
soymilk product would not increase TG levels in subjects
with metabolic syndrome or T2DM.
On the contrary, we expected to see a better TG level
in the study group from the inulin effect but the present
study could not demonstrate a positive effect from 10 g/
day of inulin to decrease TG levels. Letexier et al. dem-
onstrated TG reduction efficacy of 10 g/day of inulin
Fig. 5 Correlation between baseline LDL-c and percent LDL-c change; (a) study group (n = 115), (b) control group (n = 112)
Table 6 Number of subjects having adverse events from total visits and the adverse events categorized by severity in the study and
control groups
Number (%)
Study group (n = 116)a Control group (n = 120) Total (n = 236) RR [95 % CI] p-value
Subjects had adverse events, person 36 (31.0) 28 (23.3) 64 (27.12) 1.33 [0.87-2.03] 0.177b
Actual adverse events, event 65 (100) 51 (100) 116 (100)
Serious adverse events
Bloating 0 (0) 1 (1.96) 1 (0.86)
Hepatitis 0 (0) 1 (1.96) 1 (0.86)
Severe diarrhea 1 (1.54) 1 (1.96) 2 (1.72)
Non-serious adverse events
Bloating 50 (76.92) 33 (64.72) 83 (71.56)
Abdominal cramp 0 (0) 1 (1.96) 1 (0.86)
Nausea 0 (0) 4 (7.84) 4 (3.45)
Vomiting 1 (1.54) 1 (1.96) 2 (1.72)
Increase defecation 2 (3.08) 0 (0) 2 (1.72)
Diarrhea 4 (6.15) 4 (7.84) 8 (6.90)
Constipation 2 (3.08) 2 (3.92) 4 (3.45)
Other 5 (7.69) 3 (5.88) 8 (6.90)
a3 subjects loss to follow up before the week 2, 1 subject requested to withdraw due to pregnancy
bPearson Chi-square
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when it was consumed with a low-fat, high-carbohydrate
(LF/HC) diet [17]. Consumption of a LF/HC diet in-
creased TG levels in both fasting and postprandial states
by elevations of VLDL and chylomicrons in both states
[35]. The mechanism of an LF/HC diet to increase TG
levels was decreased VLDL clearance from the blood by
lipoprotein lipase rather than increased VLDL secretion
or de novo lipogenesis. The decreased VLDL clearance
was possibly due to competition between VLDL and
chylomicron remnants on lipoprotein lipase [36]. Thus
consuming inulin together with an LF/HC diet might
improve TG level by inhibiting carbohydrate absorption,
resulting in reduction of chylomicron remnants released
by the intestine. In our study, there were no changes in
the dietary pattern of a LF/HC diet and there was no
monitoring of the dietary pattern, thus the TG reduction
effect of the inulin in the present study was unseen. We
did not measure the apolipoprotein (Apo) B100 which
reflects VLDL production and Apo B48 which reflects
chylomicron assembly by the intestine, thus we did not
know whether the source of TG in our subjects came
from de novo lipogenesis or a decrease in VLDL clear-
ance by competition from chylomicron remnants. The
baseline TG level might be another important factor for
inulin efficacy. Jackson KG et al. demonstrated the effect
of 10 g inulin sachets add-on in water, tea, coffee, orange
juice, soup, breakfast cereal or yoghurt on TG reduction
and concluded that the percent TG change was corre-
lated with the initial TG concentration, particularly in
subjects in whom fasting TG levels were greater than
132.8 mg/dl [37]. Since the baseline median TG level in
the present study was lower than 100 mg/dl, inulin effi-
cacy was not seen in this study group.
The phytosterols and inulin-enriched soymilk and the
standard soymilk did not alter glycemic levels in either
the study group or the control group (Supplementary 1).
However, the present study did not include diabetic pa-
tients into the study, thus we could not determine the
effect of soymilk products on glycemic level in diabetic
patients.
Occurrences of adverse events in both groups were
similar and usually well-tolerated. Bloating was the most
common adverse effect in both of the study and control
groups, which accounted for 71.56 % of overall adverse
events and seemed to be more common in the phytos-
terols and inulin-enriched soymilk group. Neither of the
soymilk products contained lactose so the possible cause
of bloating was soy protein intolerance. Since inulin is a
non-digestible carbohydrate and its fermentation pos-
sibly causes the intestinal gas which may explain why
the bloating was more common in the study group [38].
There were 4 serious adverse events, one intolerable
diarrhea in the study group and 3 events in the control
group that included an intolerable bloating, an
intolerable diarrhea and hepatitis. Therefore, the phytos-
terols and inulin-enriched soymilk seemed to be as
equally safe as the standard soymilk.
The strengths of the present study were 1) the subjects
included in the study were randomized well as indicated
by the comparable baseline characteristics in both
groups, 2) the soymilk products were blinded to both
subjects and investigators, 3) overall 94.58 % of the data
were complete and 4) all subjects enrolled into the study
were statin-naïve, so the present study proved the pure
effect of phytosterols. The present study also encouraged
the role of phytosterols-enriched soymilk to improve the
LDL-c level among people who live in an urban area.
Limitations of the present study were 1) all subjects
enrolled into the study were statin-naïve, thus we could
not determine additional or synergistic effect of phytos-
terols on those who had prior statin-use, 2) the aim of
the study was to determine the short term effect on lipid
profile, so the benefit on cardiovascular outcome was
undetermined by the present study and 3) the homogen-
eity of subjects who were non-DM and metabolically
lean limited the application of the study to T2DM or
metabolic syndrome subjects.
Conclusions
Consumption of soymilk containing 2 g of phytosterols
and 10 g of inulin reduced LDL-c and TC better than
standard soymilk. The LDL-c lowering efficacy was
clearly seen from the second week. The phytosterols and
inulin-enriched soymilk had no effect on TG, HDL-c
and glycemic levels among the non-diabetic subjects and
it was as safe as the standard soymilk. The phytosterols and
inulin-enriched soymilk is an alternative way to reduce
LDL-c levels to reduce the risk of cardiovascular disease.
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